Abstract
ObjectiveTo characterise the molecular pathways impacted by the pharmacologic effects of the Janus kinase (JAK) 1 and JAK2 inhibitor baricitinib in SLE.MethodsIn a phase II, 24-week, randomised, placebo-controlled, double-blind study...
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have